Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Avrobio Inc (AVRO)

Avrobio Inc (AVRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
AVROBIO Announces Leadership Transition Business Wire - Mon May 1, 2023

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as interim Chief...

AVRO : 16.8000 (-1.41%)
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update Business Wire - Thu Mar 23, 2023

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year...

AVRO : 16.8000 (-1.41%)
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference Business Wire - Fri Mar 3, 2023

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled...

AVRO : 16.8000 (-1.41%)
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023 Business Wire - Thu Feb 9, 2023

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updated data suggesting complete biochemical...

AVRO : 16.8000 (-1.41%)
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Thu Jan 5, 2023

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500...

AVRO : 16.8000 (-1.41%)
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy Business Wire - Wed Dec 7, 2022

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced new interim pharmacokinetic, pharmacodynamic and...

AVRO : 16.8000 (-1.41%)
AVROBIO to Share Comprehensive Gaucher Disease Program Update Business Wire - Thu Nov 17, 2022

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease Program...

AVRO : 16.8000 (-1.41%)
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update Business Wire - Tue Nov 8, 2022

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept....

AVRO : 16.8000 (-1.41%)
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit Business Wire - Mon Nov 7, 2022

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual...

AVRO : 16.8000 (-1.41%)
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Thu Nov 3, 2022

AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 13,000...

AVRO : 16.8000 (-1.41%)

Barchart Exclusives

C3.ai Stock: Buy, Sell, or Steer Clear? Barchart - 4 minutes ago
C3.ai stock dropped after an analyst downgraded it to “Sell.” How should investors interpret the latest news? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot